The 41st Annual EAU Congress (EAU26) was held on 13–16 March 2026 in London, United Kingdom, bringing together thousands of urology professionals from around the world. As Europe’s largest urological meeting, the congress showcased the latest research, clinical advances, and innovations in urological care.
The four-day programme included live surgery demonstrations, keynote lectures, expert panel discussions, and hands-on training organized by the European School of Urology. Interactive plenary sessions and a large industry exhibition highlighted cutting-edge pharmaceutical and medical technologies.
Here are 20 insightful posts you shouldn’t miss from leading professionals highlighting key achievements, expert perspectives, and important discussions shared during the EAU26 Congress.
20 Posts Not To Miss from EAU26
“Great presentation today using real-world evidence from the clinicians in Germany and Canada. Duration matters. Look at the HR hazard ratio of CR duration. https://urosource.uroweb.org/resource-centres/EAU26/267832/poster”
“Another milestone at EAU26 London. Today we hosted the joint UBE European Association of Urology (EAU) session with Confederación Americana de Urología (CAU) : two continents, one shared commitment to advancing urology. Proud to co-chair alongside Dr. Zampolli in his first UBE session as CAU President. This is what global urology looks like.”
Sia Daneshmand:
“Antoni Vilaseca presenting promising early data for intravesical erdafitinib (Erda-iDRS) “TAR 210” in NMIBC presented at EAU26 83% 12-mo RFS as adjuvant therapy in HR NMIBC (n=26) 89% CR at 6 months in IR NMIBC ablative cohort Targeted #FGFR therapy moving earlier into NMIBC disease states.”
“Brian F. Chapin presents best systemic therapy trial +/- prostatectomy n=120 randomised phase II trial in prostate cancer. No observed benefit for prostatectomy . Ongoing recruitment for SWOG-1802, pls support this important clinical trial”
“Proud moment and HUGE news from EAU26: PRIMARY2 shows PSMA PET/CT can safely halve prostate biopsies in men with equivocal MRI, avoiding biopsy in 49% without missing cancer. https://uroweb.org/news/scan-that-makes-prostate-cancer-cells-glow-could-cut-need-for-biopsies-2”
“Gamechanger PRIMARY2 RCT EAU26, presented and in press The Lancet Oncology. PSMA-PET CT in men with equivocal or -ve MRI but red flags results reduces biopsy by 49% and has non-inferior csPCa detection to template biopsy in all. Proud to be part of this”
“Standing room only … but there are some seats open in the front; come on in! Rapid Fire Debates: common problems and controversies in Bladder Cancer ; 9th Edition Orange Area eURO 2: ”
“EAU 2026 opens with the plenary session on oligometastatic prostate cancer:
Perfect space for a team collaboration!
Compliments to our Colleagues Urologists!”
“What a fantastic first day of EAU2026. Strong USANZ presence and presentations.”
“Discussion EAU26 about the future of cystectomy neoadjuvant treatment and radiotherapy in muscle invasive bladder cancer. Things are changing rapidly. With pCR rates >50% for EVP many patients will want to keep their bladders. An era of ‘EVP 1st and ask questions later’ maybe a reality soon. Generation of EVP bladder sparing data is a priority.”
“Very grateful that our paper: The interplay between mutagenesis and extrachromosomal DNA shapes urothelial cancer evolution received the 2026 EAU Best Paper on Fundamental Research Award.
https://nature.com/articles/s41586-024-07955-3 I will be at EAU26 in London and look forward to seeing friends and colleagues. If you want to talk science, Bladder Cancer, or cancer evolution, let’s connect. ”
“As we head into EAU26, I’m thrilled to see that PROGRxN-BCa is now included in the newest EAU NMIBC guidelines! Grateful to Paolo Gontero
and the entire guidelines panel for including our work! : https://doi.org/10.1016/j.eururo.2025.09.4145”
“LBA – CAPTAIN RCT EAU26 MRI-guided TULSA vs RP for IR PCa @urotoday
TULSA vs RP: – Superior 6-mo safety (continence + EF: 50% vs 24%, RR 2.1) – EBL: 0 vs 150 cc – LOS: 0.3 vs 1.1 d – Less pain, faster recovery – Hospitalizations: 0.7% vs 6.3% Primary Onc EP (FF additional prostate Rx) pending”
“EAU26 Intensification strategies in HR-NMIBC Dr. Xylinas reviews CREST, ALBAN, POTOMAC ALBAN atezolizumab + BCG → no EFS benefit CREST sasanlimab + BCG → improved EFS (HR 0.68) POTOMAC durvalumab + BCG → improved DFS (HR 0.68) Benefit mainly driven by ↓ high-grade recurrence BCG maintenance for 2y remains critical”
“EAU26 TiP SURF303: Ph 2a/b trial of selective FGFR3-inh dabogratinib (TYRA-300) in LH UTUC FGFR3 alterations present in ~80–96% of LG UTUC → strong biologic rationale for selective FGFR3 inhibition Randomized dose cohorts • 60 mg QD vs 80 mg QD (n≈25 per cohort) Key eligibility • LR/LG UTUC per AUA • ≥1 marker lesion ≥5 mm • No HG disease or adenopathy Primary endpoint • CR within 6 months in FGFR3-altered LG UTUC Secondary endpoints • CR in all LG UTUC • Duration of response (≤36 mos) • Renal preservation • Safety/tolerability”
“Very happy to have the first signed copy of the HOLEP manual in block form by Dr. Fernando Gomez Sancha, a nice souvenir from London”
“EAU26 day1 recap: – PET scan to reduce unnecessary biopsies in PCa by 50%. Fabulous randomized trial by Australian in Primary2 study. Cannot wait to read the paper soon. – Role of MRI in PCa by C. Moore -and of course amazing talk by Rannikko Antti on active survival.”
“ProstaCancer early detection Lots to look forward to in future trials and implementing modern appproahces to screening.”
“Development of a novel 68Ga-labeled radiotracer targeting carbonic anhydrase IX for diagnosis of clear cell Renal Cell Carcinoma. Presentation by Tonghu Liu. EAU26 written coverage by Zach Klaassen > http://bit.ly/3NovcuC”
“LBA – RCT in large NMIBC (>3 cm): Holmium laser en-bloc resection vs conventional TURBT EAU26
• Bladder perf: 2.2% vs 21.6%, p=0.004 • Catheterization: 24 vs 48 hrs, p=0.031 • Improved path staging 35 mo F/U: DFS and OS similar, supports en-bloc resection for large tumors”
Find more exclusive oncology content on OncoDaily.
Written by Nare Hovhannisyan, MD